Stockscreener 앱 받기
14.55
2.51%
-0.375
시간 외 거래:
14.55
전일 마감가:
$14.93
열려 있는:
$14.57
하루 거래량:
2.00M
Relative Volume:
1.36
시가총액:
$2.14B
수익:
$340.81M
순이익/손실:
$-419.65M
주가수익비율:
-5.1053
EPS:
-2.85
순현금흐름:
$-402.10M
1주 성능:
-1.02%
1개월 성능:
+2.03%
6개월 성능:
-36.66%
1년 성능:
-34.22%
1일 변동 폭
$14.19
$14.96
1주일 범위
$14.19
$15.69
52주 변동 폭
$10.57
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
명칭
Denali Therapeutics Inc
전화
(650) 866-8547
주소
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
DNLI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
14.55 | 2.14B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 재개 | Morgan Stanley | Overweight |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2025-01-07 | 개시 | Robert W. Baird | Outperform |
| 2025-01-03 | 개시 | William Blair | Outperform |
| 2024-12-16 | 업그레이드 | Stifel | Hold → Buy |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-10-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 개시 | B. Riley Securities | Buy |
| 2023-01-30 | 개시 | SVB Securities | Outperform |
| 2022-12-05 | 개시 | Cowen | Outperform |
| 2022-11-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-02 | 개시 | BofA Securities | Buy |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-09-21 | 개시 | Oppenheimer | Outperform |
| 2021-09-01 | 개시 | SMBC Nikko | Outperform |
| 2021-05-18 | 개시 | UBS | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-02-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-02-24 | 개시 | Jefferies | Buy |
| 2020-02-19 | 개시 | Stifel | Hold |
| 2020-01-27 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-26 | 개시 | Wedbush | Neutral |
| 2019-09-13 | 개시 | Nomura | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 개시 | Janney | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 개시 | Goldman | Neutral |
| 2018-01-02 | 개시 | JP Morgan | Overweight |
| 2018-01-02 | 개시 | Morgan Stanley | Overweight |
모두보기
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
(DNLI) Investment Analysis - news.stocktradersdaily.com
Transcript : Denali Therapeutics Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 01 - marketscreener.com
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Ameriprise Financial Inc. Has $341,000 Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
15,100 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Acquired by Two Sigma Advisers LP - Defense World
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report? - Yahoo Finance
Denali Therapeutics Enters Registration Rights Agreement - TipRanks
(DNLI) On The My Stocks Page - news.stocktradersdaily.com
Q2 EPS Estimate for Denali Therapeutics Boosted by Analyst - Defense World
Nuveen Asset Management LLC Sells 360,243 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Stifel maintains Buy on Denali Therapeutics stock, $37 target - Investing.com Australia
Stifel Nicolaus Reaffirms Their Buy Rating on Denali Therapeutics (DNLI) - The Globe and Mail
Bank of America Corp DE Trims Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Stifel maintains Buy on Denali Therapeutics stock, $37 target By Investing.com - Investing.com UK
BNP Paribas Financial Markets Sells 11,682 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com
Millennium Management LLC Acquires 344,056 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
When (DNLI) Moves Investors should Listen - news.stocktradersdaily.com
Hunter Syndrome Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com
Denali Therapeutics (DNLI) Receives a Price Target Adjustment fr - GuruFocus
Denali Therapeutics (DNLI) Receives a Price Target Adjustment from B of A Securities | DNLI Stock News - GuruFocus
Denali Therapeutics (DNLI) Target Price Adjusted by Analyst | DN - GuruFocus
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of “Buy” from Analysts - Defense World
Denali Therapeutics shares fall after price target cut to $32 By Investing.com - Investing.com Nigeria
HC Wainwright Issues Optimistic Estimate for DNLI Earnings - Defense World
Where are the Opportunities in (DNLI) - news.stocktradersdaily.com
Q1 Earnings Forecast for DNLI Issued By Wedbush - Defense World
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus - MSN
Hunter Syndrome Treatment Market Expands with Enzyme - openPR.com
Denali Therapeutics (DNLI) Price Target Reduced to $30 by Analys - GuruFocus
Denali Therapeutics shares fall after price target cut to $32 - Investing.com
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth - Yahoo Finance
Denali Therapeutics (DNLI) Price Target Revised Amid Strategic D - GuruFocus
Denali Therapeutics Advances Pipeline Amid Financial Loss - TipRanks
Denali Therapeutics (DNLI) Target Price Adjusted by HC Wainwrigh - GuruFocus
Denali Therapeutics (DNLI) Target Price Adjusted by HC Wainwright & Co. | DNLI Stock News - GuruFocus
Denali Therapeutics (DNLI) Price Target Revised Amid Strategic Developments | DNLI Stock News - GuruFocus
Denali Therapeutics price target lowered to $32 from $80 at H.C. Wainwright - TipRanks
Decoding Denali Therapeutics Inc (DNLI): A Strategic SWOT Insigh - GuruFocus
Denali Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Denali Therapeutics Reports First Quarter 2025 Financial - GlobeNewswire
Breakthrough Hunter Syndrome Drug Heads to FDA: Denali's Brain-Barrier Treatment Could Transform Patient Care - Stock Titan
Eli Lilly signs $415m deal for Alchemab’s ALS therapy - Pharmaceutical Technology
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - TradingView
Biogen (BIIB) Completes Enrollment for Parkinson's Treatment Stu - GuruFocus
First Week of December 19th Options Trading For Denali Therapeutics (DNLI) - Nasdaq
(DNLI) Technical Data - news.stocktradersdaily.com
Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA - openPR.com
Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA Insights, Clinical Trials, and Key Companies Involved by DelveInsight | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma - The Globe and Mail
Denali Announces Rolling Regulatory Submission of Tividenofusp Alfa for Hunter Syndrome - Neurology live
Denali Therapeutics Inc (DNLI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):